Saphnelo (anifrolumab) is the first biologic drug for SLE to be approved in Europe that is not restricted to patients with a high degree of disease activity, according to AZ, which also notes it ...

with newer medicines like GSK's Benlysta (belimumab), AstraZeneca's Saphnelo (anifrolumab), and Otsuka's Lupkynis (voclosporin). For Biogen, dapirolizumab pegol is part of a push into the ...

Patients with radiographic axial spondyloarthritis who receive ixekizumab biweekly demonstrate lower sacroiliac joint erosion and increased the backfill of new tissue through 52 weeks, according ...